Categories
Change Password!
Reset Password!
Mycophenolate mofetil provides greater symptom relief and better overall outcomes than Azathioprine, likely due to its more effective modulation of the immune response.
A recent randomized controlled trial published in the “International Journal of Dermatology” has shed new light on the treatment of chronic actinic dermatitis (CAD), a rare and challenging skin condition triggered by sun exposure. This study by Sanjeev Handa and colleagues compared the effectiveness and safety of Azathioprine versus Mycophenolate mofetil (MMF), revealing MMF as the superior option. The aim was to address evidence gaps in the treatment of CAD by comparing the structured use of Azathioprine and MMF.
People were randomly assigned to receive either of the therapies under focus- Azathioprine or MMF to be used for 12 weeks. Key outcomes comprised of the Dermatology Life Quality Index (DLQI) scores and Eczema Area and Severity Index (EASI) to be noted both at the start and after the specified period. MMF led to a markedly greater reduction in EASI scores—78.3% compared to 68.3% for Azathioprine. Although both treatments improved quality of life scores, the differences were insignificant amongst the groups.
Markedly, longer disease duration and outdoor occupations were linked to poorer treatment responses. The adverse effects were in line with expectations, one patient had to stop Azathioprine due to hypersensitivity. This study highlights the promising efficacy of MMF over Azathioprine in managing CAD, yet emphasizes the need for further investigation into emerging treatments and prognostic factors for better management of this skin condition which arises due to photosensitivity.
International Journal of Dermatology
Efficacy and safety of Azathioprine versus mycophenolate mofetil in chronic actinic dermatitis in skin of color: results of a randomized controlled trial
Sanjeev Handa et al.
Comments (0)